Neogenomics (NEO) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$0.07.
- Neogenomics' EPS (Weighted Average and Diluted) rose 4166.67% to -$0.07 in Q4 2025 from the same period last year, while for Dec 2025 it was -$0.83, marking a year-over-year decrease of 3387.1%. This contributed to the annual value of -$0.84 for FY2025, which is 3548.39% down from last year.
- Neogenomics' EPS (Weighted Average and Diluted) amounted to -$0.07 in Q4 2025, which was up 4166.67% from -$0.21 recorded in Q3 2025.
- In the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) ranged from a high of $0.59 in Q2 2021 and a low of -$0.4 during Q1 2022
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.17, with a median of -$0.19 in 2021.
- Examining YoY changes over the last 5 years, Neogenomics' EPS (Weighted Average and Diluted) showed a top increase of 108333.33% in 2021 and a maximum decrease of 52500.0% in 2021.
- Neogenomics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.35 in 2021, then surged by 48.57% to -$0.18 in 2022, then soared by 38.89% to -$0.11 in 2023, then fell by 9.09% to -$0.12 in 2024, then soared by 41.67% to -$0.07 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.07 in Q4 2025, compared to -$0.21 in Q3 2025 and -$0.35 in Q2 2025.